Trial · NCT07897448
A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
NCT07897448, Phase 1, Phase 2, Not yet recruiting, Grand Theravac Life Sciences (Hangzhou) Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB). Trials, record NCT07897448. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897448
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
- NCT number
- NCT07897448
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 105 participants, estimated
- Lead sponsor
- Grand Theravac Life Sciences (Hangzhou) Co., Ltd.
- Conditions
- Chronic Hepatitis B
- Interventions
- AHB-137, TVAX-008, AHB-137, Placebo
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) in Phase I | From the first dose of study treatment through the last study visit (up to Week 72) | Treatment-emergent adverse events (TEAEs) will be assessed during the protocol-defined observation period. The percentage of participants experiencing at least one TEAE will be reported. |
| Primary | Percentage of Participants Achieving Clinical Cure (Functional Cure) at 24 Weeks After Discontinuation of All Chronic Hepatitis B Treatments in Phase II | 24 weeks after discontinuation of all chronic hepatitis B treatments (up to Week 72) | Clinical cure is defined as HBsAg clearance (\<0.05 IU/mL) and sustained HBV DNA suppression (\<LLOQ), allowing transient viral rebound, at 24 weeks after discontinuation of all CHB treatments, regardless of HBsAb status. The percentage of participants achieving clinical cure will be reported. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07897448
GET https://conductscience.org/api/trials/v1/NCT07897448/registered